Development

Articles

Nanoform and Herantis have signed a biologics proof of concept agreement for formulation proof of concept projects aimed at improving nasal drug delivery to the brain.

Nanoform, Herantis Collaborate on Nasal Drug Delivery to the Brain of Biologics

The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.

Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.

Exploring the Therapeutic Value of Blood Components

Feliza Mirasol is the science editor for 

Open communication and transparency coupled with technical expertise foster strong long-term manufacturing partnerships.

Selecting the Right-Fit Partner for Biotherapeutic Development

The collaboration will focus on up to three types of lung and gastrointestinal cancers.

Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%. 

rBIO Hits Key Lab Milestone with Synthetic Production of Insulin

The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.

Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination

The manufacture of gene therapy vectors is shifting to more modern technologies.

Modernizing Bioprocessing for Gene Therapy Viral Vectors

Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.

Cellular and Gene Therapies Face a Manufacturing Capacity Crunch

The acquisition will support the accelerated commercialization of Kyslecel (autologous pancreatic islets), Koligo’s personalized cell therapy for treating pancreatitis.

Biologics APIs